Navigation Links
Array BioPharma to Present at the NewsMakers in the Biotech Industry Conference
Date:9/24/2013

BOULDER, Colo., Sept. 24, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the NewsMakers in the Biotech Industry Conference.  The public is welcome to participate in the conference through webcasts on the Array BioPharma website:  www.arraybiopharma.com.(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Event:NewsMakers in the Biotech Industry ConferenceDate:Friday, September 27, 2013Time:10:30 a.m. Eastern Time Location:Millennium Broadway Hotel, New York, NYAbout Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis began a Phase 3 trial evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in patients with BRAF-mutant melanoma in 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and expects to begin a Phase 3 trial in patients with non-small cell lung cancer in 2013.  Two other wholly-owned drugs, ARRY-520 and ARRY-614, are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013.  For more information on Array, please go to www.arraybiopharma.com.
CONTACT: Tricia Haugeto
Array BioPharma Inc.
303-386-1193
thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. New palm-sized microarray technique grows 1,200 individual cultures of microbes
2. DNA Microarray 2013 Market Report: A Focus on Sales Growth
3. Markets for PCR, DNA Microarray, DNA Sequencing, Mass Spectrometry and Flow Cytometry to Exceed $50 billion by 2015
4. IBNs Droplet Array sheds light on drug-resistant cancer stem cells
5. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
6. Exclusive agreement to distribute Affinity Biosensors Archimedes system extends Malvern Instruments biopharma solutions
7. New research on potential avocado health benefits presented at International Congress of Nutrition
8. Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma
9. Yin-yang effect of sodium and chloride presents salt conundrum
10. Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients
11. Efficacy of acupressure to relieve migraine nausea presented at International Headache Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2019)... ... ... Fluxion Biosciences, a leading developer of precision solutions for life science research ... further development of its ERASE-Seq liquid biopsy technology. The Phase I grant will have ... Mian at the Cleveland Clinic. , Liquid biopsies offer the potential to improve treatment ...
(Date:2/22/2019)... FALLS, Wisc. (PRWEB) , ... February 21, 2019 , ... ... movement is now expected when creating natural foods and beverages. It is quite common ... the fine print. Yet, meat products are not immune to this label scrutiny. ...
(Date:2/19/2019)... (PRWEB) , ... February 19, 2019 , ... ... the appointment of Mark Hozza as Chief Commercial Officer of the life science ... responsible for the performance, strategy, and alignment of all market research and media ...
Breaking Biology News(10 mins):
(Date:3/4/2019)... ... ... hot topics through free webinars presented by leading experts in pharma, biotech, medical device and ... save your place! Participate in the discussion and stay relevant in your field! , Visit ... March 20 – Implementing BYOD Across Phase II and III Clinical Trials , ...
(Date:2/27/2019)... ... February 26, 2019 , ... ... automation and IT solutions with 140 employees on both the east and west ... license in the State of New Hampshire. Sandmaier, a senior project engineer, joins ...
(Date:2/22/2019)... ... February 20, 2019 , ... Murrieta Genomics ... in the rapidly growing NGS (Next Generation Sequencing) field, have announced a partnership ... incubator. , "As an innovation center and idea incubator, we are always looking ...
(Date:2/22/2019)... ... 20, 2019 , ... Ocean Tomo Transactions, LLC will auction ... The patents in lot 92 relate to innovation for verifying human ... human users and computers through exploiting the fundamental differences between computer-based vision and ...
Breaking Biology Technology: